Mercia Asset Management – executive interview

Published on 12 October 2020

Mercia Asset Management is a regionally focused specialist asset manager with a stated intent to become the leading provider of supportive balance sheet, venture, private equity and debt capital to the UK regions, in transaction sizes typically below £10m.

Life sciences is one of Mercia’s three focus sectors, with seven of its top 20 holdings at 31 March 2020 in the sector, valued at £29m in aggregate or 33% of total portfolio value, with another c 40 earlier-stage life sciences investments held across its third-party managed funds.

In this interview, following the recent life sciences portfolio update, Dr Mark Payton (CEO), Peter Dines (COO and previous head of life sciences) and Dr Mark Wyatt (investment director) discuss Mercia’s approach to investment in the life sciences sector, the impact of COVID-19 and what this might mean for Mercia’s future investment strategy in life sciences.

Share this with friends and colleagues